Home » Dermira Nabs Fast Track Designation for Lebrikizumab
Dermira Nabs Fast Track Designation for Lebrikizumab
December 20, 2019
Dermira gained fast track designation from the FDA for its novel, investigational drug lebrikizumab for treatment of moderate-to-severe atopic dermatitis.
Lebrikizumab is currently being evaluated in two Phase 3 studies designed to confirm its safety and efficacy in patients ages 12 years and older.
Moderate-to-severe atopic dermatitis is characterized by a range of symptoms, including rashes that often cover much of the body and persistent itching.
Upcoming Events
-
21Oct